The Establishment and Maintenance of a Comprehensive Thoracic Tumor Data Registry and Bioreceptor 
Aims:The purpose of this database is to allow researchers to review and compare medical information including medical history, symptoms, medical test results, treatments and complications that people with thoracic tumor may have. Another purpose of this study is to collect leftover tissue obtained during thoracic surgery or diagnostic tests. Research testing of this tissue may help to determine the changes which lead to the development and/or spread of cancer. This information may help to develop new kinds of diagnostic
Diagnosis: Thoracic Cancer
Principal Investigator: John Howington, MD
IRB Approval Number: EH98-136
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research coordinator Ujala Bokary at 847.570.1783
Open to Enrollment: Yes

UC12-1726: A Randomized Phase II Study of IV Topotecan versus CRLX101 in the Second-Line Treatment of Recurrent Small Cell Lung Cancer
Aims: The purpose of this study is to find out what effecrts, good and/or bad, the experimental drug CRLX101 has on you and your small cell lung cancer. CRLX101 is an experimental drug that is a new formulation of an anti-cancer drug called camptothecin (CPT). Like topotecan, CPT blocks the topoisomerase I enzyme. It is hoped that this new formulation of CPT will have fewer side effects than prior formulations of CPT and will be more effective in blocking the topoisomerase I enzyme. CRLX101 has not been approved by the Food and Drug Administration for use in small cell lung cancer. 
Diagnosis: Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH13-163
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

E2511: A Phase I and Randomized Phase II Double Blind Clinical Trial of Displatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Aims: The purpospurpose of this study is two parts. In the first part of the study (phase I) we wanted to first ascertain that it is safe to allow patients to take an additional investigational pill (veliparib) along with the standard chemotherapy (cisplatin and etoposide) for the treatment of their lung cancer. Cisplatin and etoposide were chosen for this trial because the benefits and risks are well known, and because together they are one of the most effective therapies against small cell lung cancer or large cell neuroendocrine NSCC. In the second part of this study (phase II) we want to compare the effects, good and/or bad, of veliparib or a placebo (inactive pill) when combined with the standard commonly-used drugs (cisplatin and etoposide) on you and your type of lung cancer to find out which is better. If you participate in the second part of this study, you will get either veliparib or the placebo pill. You will not get both. However, you will get the standard chemotherapy drugs irrespective of which type of pill you are getting. You are being asked to take part in the phase II portion of the study.
Diagnosis: Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH13-193
Sponsor: Eastern Cooperative Oncology Group (ECOG)
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

MO22097: An Open-Label, Randomized, Phase IIIB Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) after First (1st)-line Treatment with Bevacizimab Plus a Platinum Doublet-Containing Chemotherapy
Aims: This research study will try to discover if the continuation of bevacizumab, in addition to standard 2nd &3rd line treatment, can help patients with NSCLC live longer free of tumor re-growth or spreading. The study also aims to find out if continued bevacizumb use is generally safe in combination with standard treatment for NSCLC that has progressed.
Diagnosis: Advanced Non-Squamous Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH13-242
Sponsor: F. Hoffman-La Roche Ltd. (Roche)
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

UC12-2158: NCI 9267: A Phase 2 Study of ARQ 197 in Patients with Previously Treated Malignant Mesothelioma
Aims: The purpose of this study is to determine whether ARQ 197 can shrink tumors in mesothelioma patients. This research is being done because more effective treatments need to be developed for this disease if standard treatments stop working.
Diagnosis: Malignant Mesothelioma
Principal Investigator: Nicholas Campbell, MD
Sponsor: University of Chicago
Contact: For more information, interested participants may contact research nurse, Michele Britto at 847.570.2109

RTOG 0839: Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Aims: This study will compare the effects, good and/or bad, of adding panitumumab to chemotherapy and radiation therapy. In this study, you will get chemotherapy and radiation OR radiation, chemotherapy, and panitumumab. Panitumumab is a drug that may delay or prevent tumor growth by blocking certain cellular chemical pathways that lead to tumor development. It has been approved by the FDA as a single agent for the treatment of epidermal growth factor receptor (EGFR) expression in patients with colorectal cancer whose disease has progressed after prior chemotherapy. Panitumumab has not yet been approved as a treatment for patients with lung cancer, as it has not yet been shown to be effective for the treatment of lung cancer. It is considered experimental in this study.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH13-449
Sponsor: Radiation Therapy Oncology Group (RTOG)
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

× Alternate Text